Company: NGVT
Filing Date: 2025-03-19
Form Type: PRER14A
Source: 0001308179-25-000166
Chunk: 26

Company: Ingevity Corp
Filing Date: 2025-03-19
Form: PRER14A
Chunk 26
---
 | Quality Policy;                                                                     |
| n | Responsible Care® Policy; and                                                       |
| n | Supplier Principles of Conduct.                                                     |

These materials are also available in print at no charge to any stockholder who requests a copy by writing to Corporate Secretary, Ingevity Corporation, 4920 O’Hear Ave, Suite 400, N. Charleston, SC 29405, or by email to: corporatesecretary@ingevity.com. Related party transactions The Board evaluates related party transactions consistent with Item 404 of Regulation S-K. Under its charter, the Nominating & Governance Committee is charged with reviewing all potential related party transactions and making recommendations to the Board regarding approval of any such transactions. Each year, the Company solicits information regarding potential related party transactions from directors, director nominees and executive officers, who are also required to promptly notify the Company and the Nominating and Governance Committee of any new affiliations or transactions as they arise. Transactions and affiliations disclosed by such persons are then reviewed and analyzed by our Law and Compliance department using searches run against the Company’s books and records to determine if there are any financial transactions involving the Company and such affiliates. The results of such analyses are reported to the Nominating and Governance Committee for review, analysis and determination of whether there are any related party transactions and, if any are found, whether such transactions should be approved or ratified based on the relevant circumstances. Based on a review of the transactions and affiliations reported by the Company’s directors, director nominees, and executive officers beginning in December 2024, the Nominating & Governance Committee has advised the Board that it has not identified any related party transactions since the beginning of the fiscal year ended December 31, 2024, and none are currently proposed.

| INGEVITY  |  2025 
 Proxy Statement   | 41 |

Director Compensation Ingevity’s Director compensation approval process The Board annually reviews and approves non-employee director compensation at the recommendation of the T&C Committee. This review involves a survey of director compensation at peer companies and other similarly situated companies and a discussion with our independent compensation consultant, Pearl Meyer, regarding director compensation practices. 2024 Non-employee Director compensation The 2024 non-employee director compensation program consisted of the following:

| Standard                                
 Compensation                            |     |   |         |
|:----------------------------------------|:----|:--|--------:|
| Cash Retainer                           |     | $ |  90,000 |
| Restricted Stock